Magnetic resonance maging: Liver-specific contrast agents

Clinics in Liver Disease

Volumn 6, Issue 1, 2002, Pages 73-90

  Ji, Hoon ^a   Ros, Pablo R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; ECHOVIST; GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERIC ACID; GADOTERIDOL; MANGAFODIPIR; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

CONTRAST ENHANCEMENT; CONTRAST RADIOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HEPATIC ARTERY; HEPATOBILIARY SYSTEM; HUMAN; LIVER; LIVER BLOOD FLOW; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FUNCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; TISSUE SPECIFICITY; LIVER TUMOR; METASTASIS; METHODOLOGY; PATHOLOGY;

CONTRAST MEDIA; HUMANS; LIVER; LIVER DISEASES; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING;

EID: 0036009425     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(03)00067-9     Document Type: Review

References (75)

1. MnDPDP-enhanced MRI vs dual-phase spiral CT in the detection of hepatocellular carcinoma in cirrhosis
2. Detection of focal hepatic lesions: Comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAP
3. Hepatic adenoma and focal nodular hyperplasia: MR findings with superparamagnetic iron oxide enhanced MRI
4. Liver metastases: Safety and efficacy of detection with superparamagnetic iron oxide in MR imaging
5. Detection of hepatic lesions in candidates for surgery: Comparison of ferumoxides-enhanced MR imaging and dual-phase helical CT
6. Preoperative detection of hepatocellular carcinoma: Ferumoxides-enhanced MR imaging versus combined helical CT during arterial portography and CT hepatic arteriography
7. Liver tumors in cirrhosis: Experimental study with SPIO-enhanced MR imaging
8. Value of hepatic arterial phase CT versus lipiodol ultrafluid CT in the detection of hepatocellular carcinoma
9. Hepatic tumors: Detection and characterization at 1-T MR imaging enhanced with AMI-25
10. Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. multicenter phase III clinical trials. Efficacy of early imaging
11. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg)
12. Benign hepatocellular tumors: MRI after superparamagnetic iron oxide administration
13. Enhancement of liver hemangiomas on T1-weighted MR SE images by superparamagnetic iron oxide particles
14. Hepatocellular carcinoma: Correlation between gadobenate dimeglumine-enhanced MRI and pathologic findings
15. Detection of liver metastases: Comparison of superparamagnetlc iron oxide-enhanced and unenhanced MR imaging at 1.5 T with dynamic CT, intraoperative US, and percutaneous US
16. Clinical utility and safety of MultiHance in magnetic resonance imaging of liver cancer: Results of multcenter studies in Europe and the USA
17. Liver metastases: Improved detection with dynamic gadolinium-enhanced MR imaging?
18. Differentiation of liver hemangiomas from metastases and hepatocellular carcinoma at MR imaging enhanced with blood-pool contrast agent Code-7227
19. MR imaging in the evaluation of hepatic metastases
20. Metastatic liver tumor: Circumferential versus wedge-shaped perilesional enhancement and quantitative image and pathologic correlation
21. Hepatocellular carcinoma: Are combined CT during arterial portography and CT hepatic arteriography in addition to triple-phase helical CT all necessary for preoperative evaluation?
22. Experimental hepatic dysfunction: Evaluation by MRI with Gd-EOB-DTPA
23. 3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties
24. Enhanced tumor detection in the presence of fatty liver disease: Cell-specific contrast agents
25. Definition of liver tumors in the presence of diffuse liver disease: Comparison of findings at MR imaging with positive and negative contrast agents
26. Volumetric mangafodipir trisodium-enhanced cholangiography to define intrahepatic biliary anatomy
27. Diagnostic accuracy of helical CT arterial portography and CT hepatic arteriography for hypervascular hepatocellular carcinoma in chronic liver damage. An ROC analysis
28. Gadobenate dimeglumine (BOPTA) enhanced MR imaging: Patterns of enhancement in normal liver and cirrhosis
29. Comparison between Gd-DTPA, Gd-EOB-DTPA, and Mn-DPDP in induced HCC in rats: A correlation study of MR imaging, microangiography, and histology
30. Sequential use of gadolinium chelate and mangafodipir trisodium for the assessment of focal liver lesions: Initial observations
31. Evaluation of the hepatocyte-specific contrast agent gadobenate dimeglumine for MR imaging of acute hepatitis in a rat model
32. Focal nodular hyperplasla of the liver assessment with contrast-enhanced turboflash MR imaging
33. Pre-operative detection of malignant hepatic tumours: Value of combined helical CT during arterial portography and biphasic CT during hepatic arteriography
34. MRI in focal liver disease: A comparison of small and ultra-small superparamagnetic iron oxide as hepatic contrast agents
35. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: A potential new sign for characterization of liver lesions
36. Early radiation effects on the liver demonstrated on superparamagnetic iron oxide-enhanced T1-weighted MRI
37. Arterioportal shunts in cirrhotic patients: Evaluation of the difference between tumorous and nontumorous arterioportal shunts on MR imaging with superparamagnetic iron oxide
38. Hepatocellular carcinoma: MR imaging with mangafodipir trisodium (Mn-DPDP)
39. Evaluation of regional liver damage by magnetic resonance imaging with superparamagnetic iron oxide in rat liver
40. Improved tissue characterization of focal liver lesions with ferumoxide-enhanced T1 and T2-weighted MR imaging
41. The uptake of Mn-DPDP by chemically induced RCC in rats. A correlation between contrast media enhanced MRI, tumor differentiation and vascularization
42. Abdominal MR angiography performed using blood pool contrast agents: Comparison of a new superparamagnetic iron oxide nanoparticle and a linear gadolinium polymer
43. Dynamic MR imaging and early-phase helical CT for detecting small intrahepatic metastases of hepatocellular carcinoma
44. Radiation induced liver injury detected by particulate reticuloendothelial contrast agent
45. Characterization of focal hepatic lesions with ferumoxides-enhanced T2-weighted MR imaging
46. Focal liver lesions: Evaluation of the efficacy of gadobenate dimeglumine in MR imaging - A multicenter phase III clinical study
47. Hepatic malignancies: Usefulness of acquisition of multiple arterial and portal venous phase images at dynamic gadolinium-enhanced MR imaging
48. Evaluation of the accuracy of gadobenate dimeglumine-enhanced MR imaging in the detection and characterization of focal liver lesions
49. MRI with superparamagnetic iron oxide: Efficacy in the detection and characterization of focal hepatic lesions
50. T1 effects of a bolus-injectable superparamagnetic iron oxide, SH U 555 A: Dependence on field strength and plasma concentration-preliminary clinical experience with dynamic T1-weighted MR imaging
51. Enhancement characteristics of liver metastases, hepatocellular carcinomas, and hemangiomas with Gd-EOB-DTPA: Preliminary results with dynamic MR imaging
52. Phase II clinical evaluation of Gd-EOB-DTPA: Dose, safety aspects, and pulse sequence
53. Hepatic MR imaging with ferurnoxides: A multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions
54. MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies
55. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA
56. Ferumoxide-enhanced MRI in patients with colorectal cancer and rising CEA: Surgical correlation in early recurrence
57. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: Initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227)
58. Multicentre dose-ranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging
59. Perilesional enhancement of hepatic metastases: Correlation between MR imaging and histopathologic findings - Initial observations
60. Detection of hepatic metastases: Ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography
61. Evaluation of regional liver function by gadoliniumEOB-DTPA-enhanced MR imaging
62. CT during arterial portography for the preoperative evaluation of hepatic tumors: How, when, and why?
63. Detection of focal hepatic lesions with MR imaging: Prospective comparison of T2-weighted fast spin-echo with and without fat suppression, T2-weighted breath-hold fast spin-echo, and gadolinium chelate-enhanced 3D gradient-recalled imaging
64. CT during arterial portography
65. Dynamic MR imaging of liver metastases with Gd-EOB-DTPA
66. Evaluation of hepatocyte-specific paramagnetic contrast media for MR imaging of hepatitis
67. Mn-DPDP for MR imaging of the liver. Results from the European phase III studies
68. Detection of bile duct leaks using MR cholangiography with mangfodipir trisodium (Teslascan)
69. Superparamagnetic iron oxide-enhanced versus gadolinium-enhanced MR imaging for differential diagnosis of focal liver lesions
70. Liver tumors: Comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA
71. Diagnostic efficacy of MnDPDP in MR imaging of the liver. A phase III multicentre study
72. Hepatocellular carcinoma in the cirrhotic liver: Double-contrast MR imaging for diagnosis
73. Three-dimensional contrast-enhanced MRI using an intravascular contrast agent for detection of traumatic intra-abdominal hemorrhage and abdominal parenchymal injuries: An experimental study
74. Hepatocellular carcinoma in cirrhotic livers: Detection with unenhanced and iron oxide-enhanced MR imaging
75. Small hepatocellular carcinoma in patients with chronic liver damage: Prospective comparison of detection with dynamic MR imaging and helical CT of the whole liver